WO2000072882A1 - Agents prophylactiques du purpura thrombocytopenique idiopathique - Google Patents
Agents prophylactiques du purpura thrombocytopenique idiopathique Download PDFInfo
- Publication number
- WO2000072882A1 WO2000072882A1 PCT/JP2000/003478 JP0003478W WO0072882A1 WO 2000072882 A1 WO2000072882 A1 WO 2000072882A1 JP 0003478 W JP0003478 W JP 0003478W WO 0072882 A1 WO0072882 A1 WO 0072882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- itp
- antibody
- mice
- age
- platelet
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention relates to an agent for preventing idiopathic thrombocytopenic purpura (ITP).
- ITP idiopathic thrombocytopenic purpura
- the interaction between the gp39 molecule on the CD4 + Th cell surface and the CD40 molecule on the B cell surface is essential for B cells to differentiate into antibody-producing cells upon antigen stimulation. It is known that inhibition of the action by a gp39 antagonist, such as an anti-gp39 antibody, suppresses antibody production (W095 / 06480).
- gp39 antagonists inhibit both CD4 + Th cell and B cell immune responses, gp39 antagonists can respond to autoantigens to autoimmune disease ( Attempts have been made to apply it to the treatment of systemic lupus erythematosus (SLE), ITP, etc. Disclosure of the invention
- gp39 antagonists are more susceptible from the stage at which an immune response is initiated than from starting administration at the stage where an immune response has been established once and inducing an immune unresponsiveness. We expected that it would be easier to induce responsiveness.
- Idiopathic thrombocytopenic purpura ( ⁇ ) is associated with the low-affinity IgG receptor gene (FcaRIIA). It has been suggested that genetic polymorphisms are correlated (Williams et al., British Journal of Haematology 101: 779-82, 1998). In the future, single nucleotide polymorphisms (SNPs) It is presumed that if the development of genetic diagnosis methods is advanced and SNPs with stronger correlation are found, the onset of ITP will be predictable. For those who are expected to develop ITP, administration of gp39 antagonist that induces immune unresponsiveness from the stage when the immune response to platelets starts is compared with administration after administration of ITP Thus, it is considered that unresponsiveness can be more easily induced.
- SNPs single nucleotide polymorphisms
- gp39 antagonist is administered to patients with ITP in remission by administering steroids, etc., and if the immune response to platelets induced in the exacerbation period can be suppressed to induce unresponsiveness, Can be prolonged, and its therapeutic value is considered to be high.
- mice genetically developing ITP-like pathologies thrombocytopenia and antiplatelet autoantibody production
- age and male mice NZW X BXSB mice
- an anti-gp39 antibody which is a gp39 antagonist
- the present invention provides an ITP prophylactic agent comprising, as an active ingredient, a drug that inhibits an interaction between a receptor gp39 that mediates a contact-dependent helper effector function on the surface of a T cell and CD40 on an antigen-presenting cell surface.
- a drug that inhibits an interaction between a receptor gp39 that mediates a contact-dependent helper effector function on the surface of a T cell and CD40 on an antigen-presenting cell surface.
- the present invention is the interaction between the production of ITP preventive agent, a receptor g P 39 for medium Rupaefeku evening one function contact dependent to the on T cell surfaces, and CD40 on antigen presenting cell surface
- ITP preventive agent a receptor g P 39 for medium Rupaefeku evening one function contact dependent to the on T cell surfaces
- CD40 on antigen presenting cell surface
- the present invention provides a patient predicted to develop idiopathic thrombocytopenic purpura (ITP), a receptor gp39 that mediates a contact-dependent helper effector function on the surface of T cells, Provided is a method for preventing the development of ITP by administering an agent that inhibits the interaction with CD40 on the surface of antigen-presenting cells.
- ITP idiopathic thrombocytopenic purpura
- the agent that inhibits the interaction between the receptor gp39, which mediates contact-dependent helper function on the T cell surface, and CD40 on the antigen-presenting cell surface is preferably an anti-gp39 antibody .
- FIG. 1 shows the inhibitory effect of the anti-gp39 antibody MR1 on lethality in (NZW X BXSB) F mice.
- ⁇ MR1 (500 g / mouse),
- ⁇ control group,
- FIG. 2 shows the inhibitory effect of MR1 on thrombocytopenia in (NZW X BXSB) F! Mice.
- ⁇ MR1 (500 ⁇ g / mouse), ⁇ : control group, *: p ⁇ 0.05 (Analysis of variance over time). Values indicate the standard error of the mean of surviving mice.
- FIG. 3 shows the inhibitory effect of MR1 on (NZW ⁇ BXSB) F, mouse anti-platelet IgG antibody titer in plasma.
- ⁇ MR1 (500 ⁇ g / mouse), ⁇ : control group, *: p ⁇ 0.05 (Analysis of variance over time). Values represent the mean standard error of the surviving mice.
- FIG. 4 shows the inhibitory effect of MR1 on platelet-binding anti-platelet IgG antibody titer in (NZW X BXSB) F, mice.
- ⁇ Ml (500 / g / mouse), ⁇ : control group, *: p ⁇ 0.05 (Analysis of variance over time). Values represent the mean soil standard error in surviving mice.
- gp39 antagonist An agent that inhibits the interaction between the receptor gp39, which mediates the contact-dependent helper effector function on the surface of T cells, and CD40, on the surface of antigen-presenting cells. It is defined as an evening gonist.
- the gp39 antagonists include not only drugs that interact with gp39, but also drugs that interact with CD40.
- the gp39 antagonist is an antibody directed against gp39 (eg, a monoclonal antibody against gp39), a fragment of an antibody directed against gp39 (eg, Fab or (Fab ′) 2 fragment), a chimeric antibody or It may be a humanized antibody, soluble CD40 or soluble CD40L and fragments thereof, or any other compound that inhibits the interaction between gp39 and CD40.
- Labeled soluble CD40 is prepared by preparing soluble CD40 by, for example, the method described in Example 1 of Japanese Patent Application Laid-Open No. 6-220096, and using a suitable labeling substance such as a fluorescent substance. It can be prepared by labeling with a radioisotope or the like.
- Activated helper T cells can be prepared, for example, by activating with an anti-CD3 antibody or the like according to the method described in Example 1 of JP-A-6-220006. Evaluation of the binding of labeled soluble CD40 to activated helper T cells can be performed by FACS, for example, using fluorescently labeled soluble CD40.
- Anti-gp39 antibodies A mammal (eg, a mouse, a hamster or a heron) can be immunized with a gp39 protein or protein fragment (eg, a peptide fragment) in the form of an immunogen that elicits an immune response in the mammal.
- a mammal eg, a mouse, a hamster or a heron
- a gp39 protein or protein fragment eg, a peptide fragment
- the gp39 protein is obtained by integrating an expression vector containing the gp39 cDNA (Armitage et al., Nature, 357: 80-82, 1992; HoUembaugh et al., EMBO J., 11: 4313-4319, 1992) into a host cell, for example.
- the gp39 protein can be expressed in bacterial or mammalian cell lines and purified from culture according to standard methods. Further, for example, the protein may be expressed as a fusion protein with GST or the like, and in the case of a fusion protein with GST, it may be purified by a glutathione column.
- the gp39 peptide is based on the amino acid sequence of gp39 (Armitage et al., Nature, 357: 80-82, 1992, HoUembaugh et al "EMBO J” 11: 4313-4319, 1992) and is prepared by a known method (for example, F-inoc). Or T-boc chemical synthesis), and the synthesized peptide is allowed to enhance immunogenicity by binding to a suitable carrier, for example, KLH.
- a suitable carrier for example, KLH.
- an antiserum After immunization of the purified gp39 protein or peptide fragment with an adjuvant, an antiserum can be obtained, and if desired, a polyclonal antibody can be isolated from the antiserum.
- antibody-producing cells lymphocytes
- myeloma cells By a standard cell fusion method to immortalize the cells to obtain hybridoma cells.
- myeloma cells Such a technique is a method established in the art, and can be performed according to an appropriate manual (Harlow et al, Antibodies: A Laboratory Manual, 1998, Cold Spring Harbor Laboratory).
- monoclonal antibodies can be produced using the human B cell hybridoma method (Kozbar et al., Immunol. Today, 4: 72, 1983), the EBV-hybridoma method (Cole et al.) To produce human monoclonal antibodies. , Monoclonal Antibody in Cancer Therapy, 1985, Allen R. Bliss, Inc., pages 77-96), Combinatorial antibody library screen Other methods such as Ninging (Huse et al., Science, 246: 1275, 1989) may be used.
- the antibody herein includes a fragment of the antibody that specifically binds to gp39, for example, a Fab or (Fab,) 2 fragment.
- chimeric antibodies ie, antibodies in which the antigen-binding region is derived from a mouse monoclonal antibody and the other regions are derived from human antibodies.
- the antibodies in the present invention also include chimeric antibodies.
- Chimeric antibodies include chimeric antibodies using the entire variable region of a mouse monoclonal antibody as an antigen-binding region (Morrison et al., Proc. Natl. Acad. Sci.
- the preventive agent for ITP of the present invention is useful for preventing the onset of ITP (including relapse) in patients who are expected to develop ITP (including patients with ITP in remission due to administration of steroid compounds). Can be administered.
- Administration of the ITP prophylactic agent of the present invention can be performed by a conventional method such as injection (subcutaneous, intravenous, etc.).
- the form of the ITP prophylactic agent is appropriately selected depending on the administration method.
- a pharmaceutical composition suitable for injection a sterile aqueous solution (if water-soluble) or dispersion and a sterile injection solution or dispersion are immediately prepared. Sterile powders for cleaning.
- Pharmaceutical compositions suitable for injectable use must in each case be sterile and must be fluid to the extent that easy syringability exists.
- the compositions must be stable under the conditions of manufacture and storage and must be preserved against the action of contaminating microorganisms such as bacteria and fungi.
- Carriers include, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, and polyethylene glycol).
- a dispersion medium containing a suitable mixture thereof Proper fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and by using a surfactant. Protection from the action of microorganisms can be provided by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride, and the like in the composition. Prolonged absorption of the injectable compositions can be brought about by incorporating in the composition an agent which delays absorption, for example, aluminum monostearate per gelatin.
- Injection solutions can be prepared by mixing the required amount of the active compound (gp39 antagonist) with an appropriate solvent together with one or a combination of the above components, if necessary, followed by sterile filtration.
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred preparation methods are vacuum drying and lyophilization, which result in a powder of the active ingredient and the desired additional ingredients which have previously been sterile filtered.
- the dosage of the ITP prophylactic agent is sufficient to prevent the development of ITP, and may vary depending on the patient's age, gender, sensitivity to the drug, administration method, history of the disease, and the like.
- the anti-gp39 antibody MR1 (Noelle et al., Pro Natl. Acad. Sci. USA, 89: 6550-54, 1992) used in the following examples was obtained from PharMingen as a monoclonal antibody against mouse gp39 prepared in hamsters. It is possible (Catalog No .: PM-09020D or PM-09021D). MM-producing cells are available from American Type Culture Collection (ATCC) (ATCC No .: HB-11048).
- ATCC American Type Culture Collection
- mice used were autologous to platelets in their blood after 3 months of age. With the appearance of self-antibodies, a marked decrease in platelet count with age was observed (Ikehara, Metabolism, 26: 169-179, 1989), and is considered to be a model of ITP (Adachi et al.,
- MR1 The inhibitory effect of MR1 on lethality in (NZWxBXSB) Fi mice was examined. Natl. Acad. Sci. USA, 89: 6550-54, 1992) was purified using protein A from the culture supernatant of MR1-producing cells provided by Dr. Noel le. Used. MR1 and hamster IgG as a negative control were administered intraperitoneally to mice at a dose of 500 ⁇ g / 200 ⁇ L / time, once a week for 5 to 16 weeks of age.
- MR1 and the negative control hamster IgG were administered intraperitoneally to mice at a dose of 500 ⁇ g / 200 L / time, once a week for 5 to 16 weeks of age.
- Blood samples were collected at 5, 9, 13 and 17 weeks of age under ether anesthesia using a hematocrine capillary tube with approximately 300 / L of heparin treatment using ether matrices, and blood was collected in EDTA-treated tubes.
- the number of platelets in the collected blood was measured using a comprehensive hematology analyzer system, Technicon H ⁇ ⁇ ⁇ System (Bayer Corporation, Tarry Town, NY).
- the inhibitory effect of MR1 on (NZWx BXSB) F and anti-platelet IgG antibody titers in mouse plasma was examined.
- the anti-platelet antibody titer in plasma was measured by ELISA after reacting the plasma separated from the blood collected in Example 2 with mouse platelets fixed to glutaraldehyde on a 96-well plate, followed by detection with peroxidase-labeled anti-mouse IgG.
- the serum titer (A.U./ml) of the actual sample was calculated using the serum of a 35-week-old syngeneic mouse as a standard serum and the serum as 1000 U / ml.
- ITP idiopathic thrombocytopenic purpura
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00929921A EP1101495A4 (en) | 1999-06-01 | 2000-05-30 | PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15338399 | 1999-06-01 | ||
JP11/153383 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000072882A1 true WO2000072882A1 (fr) | 2000-12-07 |
Family
ID=15561285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/003478 WO2000072882A1 (fr) | 1999-06-01 | 2000-05-30 | Agents prophylactiques du purpura thrombocytopenique idiopathique |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1101495A4 (ja) |
WO (1) | WO2000072882A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8398987B2 (en) | 2007-01-18 | 2013-03-19 | The University Court Of The University Of Aberdeen | Use of platelet glycopeptide IIIa epitopes in the treatment of immune thrombocytopenic purpura |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2085407A1 (en) * | 2008-02-04 | 2009-08-05 | Sahltech I Göteborg AB | Treatment of idiopathic thrombocytopenic purpura |
EP3191522A1 (en) * | 2014-09-10 | 2017-07-19 | Bristol-Myers Squibb Company | Methods of treating autoimmune disease using a domain antibody directed against cd40l |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001547A2 (en) * | 1992-07-09 | 1994-01-20 | Cetus Oncology Corporation | A method for generation of antibodies to cell surface molecules |
WO1995006480A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods of prolonged suppression of humoral immunity |
WO1995006666A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
WO1997031025A1 (en) * | 1996-02-23 | 1997-08-28 | Chiron Corporation | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation |
WO1998030241A1 (en) * | 1997-01-10 | 1998-07-16 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1998039026A2 (en) * | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1999027948A2 (en) * | 1997-11-28 | 1999-06-10 | Canadian Blood Services | Use of soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
WO1999000143A1 (en) * | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
-
2000
- 2000-05-30 WO PCT/JP2000/003478 patent/WO2000072882A1/ja not_active Application Discontinuation
- 2000-05-30 EP EP00929921A patent/EP1101495A4/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994001547A2 (en) * | 1992-07-09 | 1994-01-20 | Cetus Oncology Corporation | A method for generation of antibodies to cell surface molecules |
WO1995006480A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Methods of prolonged suppression of humoral immunity |
WO1995006666A1 (en) * | 1993-09-02 | 1995-03-09 | Trustees Of Dartmouth College | Anti-gp39 antibodies and uses therefor |
WO1997031025A1 (en) * | 1996-02-23 | 1997-08-28 | Chiron Corporation | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation |
WO1998030241A1 (en) * | 1997-01-10 | 1998-07-16 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1998039026A2 (en) * | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
WO1999027948A2 (en) * | 1997-11-28 | 1999-06-10 | Canadian Blood Services | Use of soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Non-Patent Citations (1)
Title |
---|
See also references of EP1101495A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8398987B2 (en) | 2007-01-18 | 2013-03-19 | The University Court Of The University Of Aberdeen | Use of platelet glycopeptide IIIa epitopes in the treatment of immune thrombocytopenic purpura |
Also Published As
Publication number | Publication date |
---|---|
EP1101495A4 (en) | 2003-05-07 |
EP1101495A1 (en) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6665139B2 (ja) | 新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用 | |
US7063845B2 (en) | Human anti-CD40 antibodies | |
JP2023509323A (ja) | 抗ccr8抗体及びその使用 | |
US20030059427A1 (en) | Isolation and characterization of highly active anti-CD40 antibody | |
US11078285B2 (en) | Anti-TEM1 antibodies and uses thereof | |
KR20070122543A (ko) | 항-cd20 항체에 의한 염증성 장 질환 (ibd)의 치료방법 | |
MX2007012989A (es) | Metodo para tratar la demencia o la enfermedad de alheimer. | |
CN102512675A (zh) | 用于治疗多发性硬化的方法 | |
JP2020526211A (ja) | ヒトcd137に結合するアゴニスト性抗体およびその使用 | |
JP2013508392A (ja) | 自己免疫疾患における抗cd3抗体の投薬 | |
US20200239566A1 (en) | Anti-tlr4 antibodies and uses thereof | |
JP6363623B2 (ja) | 免疫グロブリンaのレベルを増大するための方法 | |
WO2019098763A2 (ko) | 알파-시누클레인에 대한 항체 및 그 용도 | |
US5942229A (en) | Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent | |
JP2840131B2 (ja) | 液性免疫の持続性抑制方法 | |
JP2007525416A (ja) | 早期活性化分子のターゲティングに基づく免疫調節 | |
JP2022525435A (ja) | Cd19抗体およびこれを使用する方法 | |
US20210236512A1 (en) | Clozapine for the treatment of a immunoglobulin driven b cell disease | |
WO2000072882A1 (fr) | Agents prophylactiques du purpura thrombocytopenique idiopathique | |
US20100129361A1 (en) | Immunosuppression with antibody against itm2a | |
JP3845735B2 (ja) | Cd40lアンタゴニストを有効成分とする天疱瘡治療剤 | |
WO2001066141A1 (fr) | Agents therapeutiques et prophylactiques diriges contre le syndrome des antiphospholipides | |
TW202311293A (zh) | 免疫療法之組合及其用途 | |
CN117203230A (zh) | 特异性识别c5a的抗体及其应用 | |
CN115925918A (zh) | 特异性识别c5a的抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2000 620988 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000929921 Country of ref document: EP Ref document number: 09762131 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000929921 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000929921 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000929921 Country of ref document: EP |